SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is the dominant focus, with traders weighing the amended upper-limb data, recent rare-disease discussions and new commercial-launch job postings as possible signs of approval. Optimism and short-squeeze speculation are countered by warnings that hiring is not proof of an FDA outcome and that a CRL remains possible; INOs approval is also cited as a positive read-through, not confirmation for CAPR.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

A steep selloff and fresh lows have put AppLovin under pressure ahead of its earnings report, with traders worried about ad-market weakness, peer results, and a possible further drop if guidance disappoints. Bulls argue the decline has outpaced the companys growth and cash generation, while bears see continued downside and are wary of holding through earnings.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A rebound in the Trump-themed meme coin is prompting short-term pump and short-squeeze speculation, but discussion is dominated by its steep losses and accusations that it is a low-utility pump-and-dump; some traders are buying the dip while others expect further declines.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

A third-party observers claim that POET was featured in Foxconns photonics ecosystem has fueled speculation about the companies collaboration and POETs optical-engine prospects. Traders disagree on how meaningful the display is without company confirmation or commercial orders, and many are looking to upcoming results for evidence of production progress and customer demand.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

TEMs volatility is being debated around Q3 earnings and its AI-enabled oncology and data business, with traders citing expanded pharmaceutical partnerships and reimbursement opportunities as bullish context. Optimists point to elevated short interest and squeeze potential, while skeptics focus on profit-taking, insider sales, valuation, and sharp pullbacks.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical stocks, which traders largely view as sector-wide pressure rather than a confirmed company-specific setback. The debate is whether the decline creates a buying opportunity ahead of earnings or reflects concerns about dilution, customer concentration, and the profitability of AI infrastructure spending.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks sharp post-earnings selloff despite a strong report and raised outlook is being tied to fears that NAND pricing growth is cooling after Kioxias cautious outlook, alongside broader weakness in chip and AI stocks. Bulls call the drop an overreaction given SanDisks results and demand, while bears argue that fading pricing momentum could signal a peak in the memory cycle.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

JMIAs steep selloff and slide toward 52-week lows have traders debating whether higher fuel and shipping costs, broader risk-off sentiment, or worries about delayed profitability and possible dilution are weighing on the shares; no single new negative operational catalyst is widely identified. Bulls are buying the dip and pointing to improving business metrics and the companys profitability targets, while skeptics want confirmation those targets remain achievable.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Traders attributed Figmas sharp move to a broader software-stock rally following reports of possible Workday acquisition talks, with some speculating that short covering amplified the move. The reaction also reflects ongoing debate over whether AI threatens Figmas design business or creates new monetization opportunities.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs steep selloff and trading near recent lows have focused discussion on the upcoming earnings report and whether the company can announce AI/data-center tenant leases; traders are skeptical about the lack of signed deals, while some expect a rebound if leases materialize. Bitcoins moves also shape sentiment toward the miner, with traders debating whether oversold conditions and heavy short interest could support a bounce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LH Stock Hits Record Levels, CHE Stock Surges To Over 52-Week Highs – Here’s What’s Driving Investor Enthusiasm

Equity

Labcorp raised its FY2026 revenue and earnings forecasts following a Q3 beat, while Chemed attracted an analyst upgrade after its VITAS business drove Q3 earnings growth.

Chemed Q3 2026 Earnings Call Transcript

Chemed (NYSE:CHE) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. Forread more...

Chemed (CHE) Tops Q3 Earnings and Revenue Estimates

Chemed (CHE) delivered earnings and revenue surprises of +5.63% and +1.60%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Chemed Executive Spencer Lee Sells 1,000 Shares for $541,040

Key PointsThe sale occurred on Aug. 21 and was valued at approximately $541,000...

CHEMED CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Chemed Corporations Directors and Officers for Breach of Fiduciary Duties CHE

Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Chemed Corporation (NYSE: CHE) failed to manage Chemed in an acceptable manner, breaching their fiduciary duties to Chemed, and whether Chemed and its shareholders have suffered...

Chemed (CHE) Up 1.7% Since Last Earnings Report: Can It Continue?

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OPCH or CHE: Which Is the Better Value Stock Right Now?

OPCH vs. CHE: Which Stock Is the Better Value Option?

Notable Monday Option Activity: CHE, ULTA, CLH

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Chemed Corp (Symbol: CHE), where a total volume of 1,425 contracts has been traded thus far today, a contract volume which is representative of approximately 142...

Daily Dividend Report: CHE,ECL,MAR,PSA,EMN,TSN

Chemed announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company's capital stock, payable on September 3, 2026, to shareholders of record as of August 17, 2026. This is a 10-cent, or 17%, increase over the 60-cent div...

• Reported GAAP EPS of $6.75 up 28.08% YoY
• Reported revenue of $690.94M up 10.57% YoY
• Chemed estimates it will be at or slightly above the high-end of full-year 2026 adjusted EPS guidance issued July 28, 2026, based on results through September 30, 2026.

Chemed reported Roto-Rooter adjusted EBITDA and margin declines, five VITAS provider numbers with $6.1M in Medicare Cap liability, and nine-month operating cash flow of $229.62M versus $254.74M in 2025.

Chemed's VITAS reported higher patient revenue and census, Roto-Rooter re-acquired California territories covering over 12M people, and Chemed estimated full-year 2026 adjusted EPS at or slightly above guidance's high-end.

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

Chemed Corp.

Bullish Sentiment

<ul class="summary-bullets"><li>Labcorp’s Q3 revenue rose 6.9% to $3.81 billion, while adjusted earnings jumped 14.5% to $4.78 per share.</li><li>Leerink raised LH’s price target to $410 from $365, while maintaining an ‘Outperform’ rating, according to The Fly.</li><li>Jefferies upgraded Chemed after it posted a 10.6% increase in Q3 revenue to&nbsp; $690.9 million.</li></ul>Shares of Labcorp (LH) surged to record levels, while Chemed (CHE) shares jumped to over 52-week highs on Wednesday, fueled by stronger-than-expected third-quarter earnings and bullish Wall Street action.<a class="mention" data-mention="$LH" data-symbol-id="LH" href="https://stocktwits.com/symbol/LH" target="_blank">LH shares</a> were up around 10.4% at the time of writing, while <a href="https://stocktwits.com/symbol/CHE">CHE stock</a> gained 9%, reaching its highest level since June 2025.<h2 class="st-heading-2">Labcorp Raises FY2026 Earnings Guidance</h2>Labcorp, which provides medical laboratory testing and diagnostic services, reported a 6.9% increase in third-quarter (Q3) revenue to $3.81 billion, beating Wall Street estimates of $3.76 billion, according to Fiscal.ai. Adjusted earnings per share increased 14.5% to $4.78 from $4.18, exceeding consensus estimates of $4.64.Labcorp expects full-year 2026 revenue growth of 5.9% to 6.7%, raising the midpoint of its previous forecast by 50 basis points.&nbsp;It also increased its adjusted earnings outlook to $18.30 to $18.70 per share, up $0.18 at the midpoint. The company ended the quarter with $261.8 million in cash and $5.85 billion in total debt.Following the results, Leerink raised its price target to $410 from $365 and maintained an ‘Outperform’ rating, according to The Fly. This is an 11.6% upside potential from current levels. Barclays also lifted the stock’s price target to $380 from $330 while retaining an ‘Equal Weight’ rating.Retail sentiment surrounding LH on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes. The stock has gained about 46% so far in 2026.<h2 class="st-heading-2">Jefferies Upgrades Chemed After Q3 Earnings Beat</h2>On Wednesday, Jefferies upgraded Chemed to ‘Buy’ from ‘Hold’ and raised its price target to $620 from $520, expecting improving profit margins and steadier earnings growth to support a higher valuation.Chemed, which operates hospice care provider VITAS and plumbing and drain-cleaning business Roto-Rooter, posted a 10.6% increase in Q3 revenue to $690.9 million on Tuesday. This beat Wall Street estimates of $685.8 million. Adjusted earnings per share jumped 28.1% to $6.75, exceeding expectations of $6.44. VITAS revenue increased by 12.2%, while Roto-Rooter sales climbed by 7.5%.BofA also raised the stock’s price target to $555 from $550 but maintained a ‘Neutral’ rating. The firm said VITAS drove the earnings beat, while “Roto side of the business continues to miss.”Retail sentiment surrounding CHE on Stocktwits remained ‘bearish’ over the past 24 hours, amid ‘high’ message volumes. The stock has gained about 30% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/gmab-stock-hits-all-time-high-after-genmab-cancer-drug-trial-meets-primary-goals/cZU9Nu2R9Gh">GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stock. (Photo Courtesy of Flavio Coelho via Getty Images)

Laboratory Corp. Of America Holdings

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$7.35	--	--	N/A
Q3 '26	$6.44	$6.75	4.89%	BEAT
Q2 '26	$5.60	$6.06	8.21%	BEAT
Q1 '26	$5.30	$5.65	6.55%	BEAT
Q4 '25	$7.03	$6.42	-8.68%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

CHE Earnings

Latest Earnings Results: Q3 '26

Historical Earnings